<DOC>
	<DOC>NCT00876304</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of multiple ascending doses of PF-04802540 administered orally to subjects with schizophrenia.</brief_summary>
	<brief_title>Multiple Dose Safety Study of PF-04802540 in Subjects With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Males or females of nonchildbearing capacity aged 18 to 55 years inclusive DSMIV diagnosis of schizophrenia, stable symptoms for at least 3 months Body mass index in the range of 18 to 40 kg/m2 and body weight&gt;45 kg. Evidence or history of a primary DSM IV axis I diagnosis other than schizophrenia. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease Any condition possibly affecting drug absorption (eg, gastrectomy).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>PF-04802540 multiple dose safety study</keyword>
</DOC>